OverviewSuggest Edit

Caladrius Biosciences, Inc. (formerly NeoStem) is a cell therapy development company with cell therapy products in development based on multiple technology platforms and targeting autoimmune and cardiology indications. The Company’s subsidiary, PCT, is a development and manufacturing partner exclusively focused on the cell therapy industry. PCT provides a wide range of innovative services including product and process development, GMP manufacturing, engineering and automation, cell and tissue processing, logistics, storage, and distribution, as well as expert consulting and regulatory support.

TypePublic
Founded2006
HQNew York, NY, US
Websitecaladrius.com
Employee Ratings2.4

Latest Updates

Employees (est.) (Dec 2019)27(+8%)
Revenue (FY, 2016)$35.3 M(+57%)
Share Price (Jan 2021)$1.6
Cybersecurity ratingAMore

Key People/Management at Caladrius

David J. Mazzo

David J. Mazzo

President, Chief Executive Officer and Director
Gregory B. Brown

Gregory B. Brown

Chairman
Robert Honigberg

Robert Honigberg

Interim Chief Medical Officer
Douglas W. Losordo

Douglas W. Losordo

Executive Vice President, Global Head of Research and Development, Chief Medical Officer
Steven M. Klosk

Steven M. Klosk

Director
Todd Girolamo

Todd Girolamo

Senior Vice President, General Counsel and Corporate Secretary
Show more

Caladrius Office Locations

Caladrius has offices in New York and Rye Brook
New York, NY, US (HQ)
420 Lexington Ave # 350
Rye Brook, NY, US
800 Westchester Avenue, 800 Westchester Ave N341
Show all (2)

Caladrius Financials and Metrics

Caladrius Revenue

Caladrius's revenue was reported to be $35.28 m in FY, 2016 which is a 56.9% increase from the previous period.
USD

Net income (Q3, 2020)

(5.3m)

EBIT (Q3, 2020)

(5.3m)

Market capitalization (15-Jan-2021)

30.5m

Closing stock price (15-Jan-2021)

1.6

Cash (30-Sept-2020)

21.2m
Caladrius's current market capitalization is $30.5 m.
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

73.7m14.3m14.7m17.9m22.5m35.3m

Revenue growth, %

22%25%57%

Cost of goods sold

56.0m11.9m12.9m15.7m20.2m31.1m

Gross profit

17.7m2.4m1.7m2.3m2.3m4.1m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Revenue

18.5m17.8m22.1m3.4m4.4m2.5m4.4m3.7m4.1m4.5m4.1m3.2m5.9m5.9m7.5m8.3m9.3m7.9m

Cost of goods sold

13.5m13.8m16.3m2.7m3.7m2.4m4.2m3.0m3.8m3.7m4.0m3.4m5.8m4.8m6.2m7.1m8.6m8.0m

Gross profit

4.9m3.9m5.7m636.1k686.5k131.8k124.4k731.0k230.1k811.6k105.4k(196.3k)68.2k1.1m1.3m1.2m706.3k(119.6k)

Gross profit Margin, %

27%22%26%19%15%5%3%20%6%18%3%(6%)1%18%17%15%8%(2%)
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

12.7m13.7m46.1m19.2m20.3m14.7m29.2m10.3m14.0m

Accounts Receivable

6.5m1.1m1.9m3.1m2.6m234.5k

Prepaid Expenses

1.7m803.1k1.6m4.3m3.5m790.5k1.1m815.0k

Inventories

17.2m1.1m1.3m
Quarterly
USDQ2, 2011Q3, 2011Q1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

4.9m11.7m21.8m2.1m5.4m9.3m14.7m16.9m41.4m32.9m32.1m19.1m36.2m24.0m25.4m17.7m18.6m12.0m23.0m15.1m21.6m22.7m14.4m14.4m11.8m12.7m20.7m26.7m21.2m

Accounts Receivable

7.4m8.9m10.4m1.3m1.8m886.2k701.6k1.4m1.9m2.5m2.1m2.0m1.3m2.3m3.2m335.6k401.6k144.3k

Prepaid Expenses

1.3m1.8m2.2m882.8k3.2m995.1k993.3k1.5m1.8m2.5m4.4m4.3m4.0m3.4m3.2m5.7m920.0k793.0k1.2m1.1m1.3m1.2m1.1m461.0k1.7m989.0k

Inventories

25.0m20.6m18.0m1.2m448.0k1.5m32.0k529.4k1.5m2.0m2.1m
Annual
USDFY, 2011FY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(47.1m)(53.8m)(39.5m)(55.5m)(81.0m)(33.3m)22.2m(16.2m)(19.4m)

Depreciation and Amortization

9.0m1.6m1.6m2.2m2.7m2.7m372.0k225.0k65.0k

Inventories

4.6m(465.3k)(157.2k)(1.3m)(344.8k)(670.6k)

Cash From Operating Activities

(20.9m)(13.9m)(27.1m)(46.9m)(39.3m)(23.7m)(20.9m)(20.0m)(18.9m)
USDQ2, 2011

Financial Leverage

1.9 x
Show all financial metrics

Caladrius Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

Caladrius Online and Social Media Presence

Embed Graph

Caladrius News and Updates

Caladrius Biosciences Announces Participation in Upcoming Virtual Investor Conferences in January 2021

BASKING RIDGE, N.J., Jan. 06, 2021 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, the…

Caladrius Biosciences to Webcast Live at Life Sciences Investor Forum

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on LifeSciencesInvestorForum.com Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive present…

Caladrius Biosciences to Present at the 13th Annual LD Micro Main Event Conference

BASKING RIDGE, N.J., Dec. 09, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, today announced that David J. Mazzo, PhD, the…

Caladrius Biosciences Announces the Resignation of Dr. Douglas Losordo, Chief Medical Officer

The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer The Company retains Robert Honigberg, M.D., as interim Chief Medical Officer

Caladrius Biosciences to Present at American Heart Association’s Virtual Scientific Sessions 2020

BASKING RIDGE, N.J., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Caladrius Biosciences, Inc. (Nasdaq: CLBS) (“Caladrius” or the “Company”), a clinical-stage biopharmaceutical company dedicated to the development of cellular therapies designed to reverse disease, announces its presentation at American Heart …

Caladrius Biosciences Provides Corporate Update and Reports 2020 Third Quarter Financial Results

Conference call begins today at 4:30 p.m. Eastern time Conference call begins today at 4:30 p.m. Eastern time
Show more

Caladrius Frequently Asked Questions

  • When was Caladrius founded?

    Caladrius was founded in 2006.

  • Who are Caladrius key executives?

    Caladrius's key executives are David J. Mazzo, Gregory B. Brown and Robert Honigberg.

  • How many employees does Caladrius have?

    Caladrius has 27 employees.

  • Who are Caladrius competitors?

    Competitors of Caladrius include Beacon Clinical Research, BlackThorn Therapeutics and Sophiris.

  • Where is Caladrius headquarters?

    Caladrius headquarters is located at 420 Lexington Ave # 350, New York.

  • Where are Caladrius offices?

    Caladrius has offices in New York and Rye Brook.

  • How many offices does Caladrius have?

    Caladrius has 2 offices.